# Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

> **NCT05806580** · PHASE4 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 8 (estimated)

## Conditions studied

- Relapsed or Refractory B-cell Lymphoma

## Interventions

- **DRUG:** Relma-cel

## Key facts

- **NCT ID:** NCT05806580
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806580, "Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05806580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*